Symcel
- Diagnostics
- Medical device or technology
- Synthesis, analytic, diagnostic services
Our transformative direct metabolic method can cut the release time of advanced therapies by 70%.
Analytical technology innovator developing rapid release methods for cell & gene therapies and biologics.
There is an urgent need for rapid QC and a momentum to establish new methods, with sterility testing taking 7-21 days. Our growth based system reduce todays release time to just 2.5 days.
Based in Sweden and with offices in Boston (US). We have developed a unique biocalorimetric system that enables direct metabolic measurements at unprecedented sensitivity, enabling multiple verticals in bioprocessing, clinical testing and R&D. Broad IP, top KOL support, early commercial stage targeting 100% YoY sales increase (2MUSD in 2024).
We are raising funds to go from strong proof-of-concept to full market launch and commercial scaling.